Management of Prolonged Nausea in ESRD Patients

First-Line Pharmacologic Management

The American College of Physicians recommends initiating metoclopramide at 10-20 mg orally three to four times daily for ESRD patients with nausea, which provides both dopamine antagonism at the chemoreceptor trigger zone and prokinetic effects that address gastric stasis commonly seen in ESRD 1, 2
Alternatively, haloperidol 0.5-1 mg every 6-8 hours can be used as a first-line option for uremia-associated nausea in ESRD patients, as recommended by the National Comprehensive Cancer Network 1, 2
Prochlorperazine 5-10 mg four times daily can serve as another first-line option if metoclopramide or haloperidol are not tolerated, according to the National Comprehensive Cancer Network 1, 2

The National Comprehensive Cancer Network recommends adding a 5-HT3 antagonist, such as ondansetron 4-8 mg two to three times daily or granisetron 1 mg twice daily, if nausea persists despite dopamine antagonist therapy in ESRD patients 1, 2
Consider adding dexamethasone 4-10 mg once daily to enhance antiemetic efficacy through corticosteroid mechanisms for ESRD patients with persistent nausea, as suggested by the National Comprehensive Cancer Network 1, 2

The National Comprehensive Cancer Network suggests adding anticholinergic agents, such as scopolamine transdermal patch 1.5 mg every 72 hours, for symptoms unresponsive to previous measures in ESRD patients 1, 2
Olanzapine 5-10 mg orally daily can be considered for refractory nausea in ESRD patients, as it antagonizes multiple receptor pathways and can be highly effective, according to the National Comprehensive Cancer Network 1, 2

The National Comprehensive Cancer Network recommends ruling out severe constipation or fecal impaction, which is extremely common in ESRD patients and can cause or worsen nausea 1, 2
Check for electrolyte abnormalities, including hypercalcemia, which frequently occurs in ESRD and causes nausea, as suggested by the National Comprehensive Cancer Network 1, 2

The National Comprehensive Cancer Network recommends small, frequent meals and foods at room temperature to minimize gastric irritation in ESRD patients with nausea 1, 2
Consider dietary consultation for ongoing symptoms to optimize nutritional intake while managing nausea in ESRD patients, as suggested by the National Comprehensive Cancer Network 1, 2

The National Comprehensive Cancer Network recommends integrating palliative care services early for ESRD patients with refractory symptom burden, as these patients have high physical symptom burden and reduced quality of life 3
Discuss goals of care and consider whether maximum conservative management (without dialysis) may be appropriate for patients with severely limited life expectancy and refractory symptoms, as suggested by the Critical Care journal 3

The American Heart Association recommends caution with QT-prolonging agents, such as ondansetron, in ESRD patients who often have electrolyte abnormalities, and suggests monitoring QT intervals 4, 5
The American College of Cardiology suggests reviewing and de-escalating cardiovascular and renal medications that may contribute to nausea in ESRD patients 4, 5

Sitting upright while eating and avoiding spicy, high-fat foods can reduce symptom burden in ESRD patients with chronic nausea 4, 5